News for MorphoSys AG (MPSYF)

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a leading cause of ki

Verona Pharma has seen its share price skyrocket in anticipation of the commercial launch of its COPD treatment.

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felz…

**media[443313]**

Late breaker oral presentation to feature final results of the Phase 2 IGNAZ study of felzartamab for IgA nephropathyAdditional oral presentation to...

Interim Results for the Six Months Ended 30 June 2024

Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued execution of...

In 2022, the global oncology market was valued at approximately $203.42 billion and is expected to reach over $470.61 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2023...

Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford...

In 2022, the global oncology market was valued at approximately $203.42 billion and is expected to reach over $470.61 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2023...

The BCL-2 inhibitors market is anticipated to experience substantial growth in the upcoming years. This growth is driven by a rising number of cancer...

MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting

Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.

EQS-News: MorphoSys AG / Key word: Forecast MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces...

Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) rose sharply in pre-market trading after the company announced updated financial guidance for the second-quarter, which surpassed its previou

Massachusetts-based iRobot Corporation (IRBT), a maker of robots and home innovation products is down over 37% in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Shares of LQR House Inc. (NASDAQ: LQR) rose sharply in pre-market trading. Borg's investor group has acquired a 20% stake in LQR House. LQR House shares jumped 16.1% to $4.25 in pre-market trading Here are some other stocks moving in pre-market trading.

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.